Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

WALGREENS BOOTS ALLIANCE, INC.

(WBA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Walgreens Boots Alliance : U.S. CDC backs COVID-19 boosters for high-risk adults, workers, older Americans

09/23/2021 | 04:56pm EDT

Sept 24 (Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) on Friday backed a booster shot of the Pfizer and BioNTech COVID-19 vaccine for Americans aged 65 and older, adults with underlying medical conditions and adults in high-risk working and institutional settings.

The decision by CDC Director Rochelle Walensky is aligned with the U.S. Food and Drug Administration's authorization of the shot earlier this week and follows an August announcement of a broad booster rollout from her and other top U.S. health officials.

The CDC recommendation cleared the way for booster shots to start on Friday. One of the largest U.S. pharmacy chains, Walgreens Boots Alliance, said on Friday that boosters were available immediately for eligible individuals, and some states such as Vermont said they would be available in their vaccination centers. They will also be rolled out in long-term care facilities.

Walensky's decision broke from a recommendation on Thursday by a group of expert outside advisors to the agency who had said that a narrower group of people should receive the extra shot. The CDC director is not obliged to follow the advice of the panel.

The panel specifically excluded people in high-risk jobs and those in close living conditions on Thursday due in part to concerns about a rare heart inflammation side effect that has occurred primarily in younger men. They were also concerned the recommendation would be too broad to implement effectively.

It recommended boosters for older people and some people with medical conditions that put them at higher risk of severe COVID-19.

The authorization opens boosters to more than 20 million people who received their second Pfizer shot more than six months ago.

The CDC on Thursday told its advisers that there would be no requirements for people to submit documentation to prove that they have the underlying conditions or work in at-risk settings.

Scientists have been divided over the need for COVID-19 vaccine boosters, with some including those from the FDA and the World Health Organization saying there is inadequate evidence that they are needed by anyone other than older people and that more people around the world need a first dose of the vaccine first.

Pfizer and U.S. health officials have argued https://www.reuters.com/world/us/us-looks-covid-19-boosters-curb-virus-spread-2021-09-15 that the shots prevent hospitalizations and deaths and that emerging data indicates they can slow mild infections as well.

The highly transmissible Delta variant of the coronavirus has driven a surge in COVID-19 cases in the United States that peaked on Sept. 1 and has since fallen about 25% to just over 120,000 cases per day, based on a 7-day moving average.

Walensky said her agency had to make recommendations based on complex, often imperfect data.

"In a pandemic, even with uncertainty, we must take actions that we anticipate will do the greatest good," she said in a statement.

'ANYONE CAN SHOW UP'

SVB Leerink analyst Geoffrey Porges said he expects many of the "worried well" to seek out booster shots in the coming weeks because of the CDC's loose requirement on who is eligible.

"That literally means anyone can show up and say I’m at an increased risk of getting re-infected," Porges said.

The United States had authorized extra shots for those with compromised immune systems last month and around 2.3 million people have already received a third shot, according to the CDC.

Because the FDA has not yet considered Moderna's application for boosters and Johnson & Johnson has not yet applied for one, Pfizer is likely to benefit, he said.

Pfizer shares were down slightly on Friday, while Moderna shares fell more than 3%.

Bernd Salzberger, head of infectiology at Regensburg University Hospital in Germany, said given uncertainty over the durability of protection, experts could easily come to different conclusions over who should be eligible for boosters and when.

"The United States is currently undergoing a more severe wave of infections than here because there are many more unvaccinated in several states, mainly in the South. That could be a reason for someone to say we must protect healthcare workers in particular," Salzberger said.

The CDC said people 65 years and older should get a booster and also recommended the shots for all adults over 50 with underlying conditions, such as cancer or diabetes.

It said, based on individual benefits and risks, 18- to 49-year-olds with underlying medical conditions may get a booster, and also people 18 to 64 at increased risk of exposure and transmission due to occupational or institutional settings.

The CDC said about 26 million people would now be eligible for a Pfizer/BioNTech booster, including 13 million aged 65 or older.

William Schaffner, an infectious disease expert at Vanderbilt University Medical Center, said the shots will be widely available under this policy.

"I’m skeptical that locations will be overwhelmed, but there may be some locations, particularly in high-income neighborhoods, where they might get a lot of people interested," Schaffner said.

(Additional reporting by Manojna Maddipatla in Bengaluru and Ludwig Burger in Frankfurt; Editing by Chizu Nomiyama, Mark Porter and Bill Berkrot)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
MODERNA, INC. -0.37% 333.61 Delayed Quote.219.34%
WALGREENS BOOTS ALLIANCE, INC. -0.81% 48.01 Delayed Quote.20.39%
All news about WALGREENS BOOTS ALLIANCE, INC.
10/18WALGREENS : Flu Index Shows Flu Activity Is Up 23 Percent Compared to Last Flu Season as P..
BU
10/15S&P 500 Posts 1.8% Weekly Gain, Strongest Since July, Amid Positive Start to Q3 Results..
MT
10/15WALGREENS BOOTS ALLIANCE : Truist Securities Adjusts Walgreens Boots Alliance PT to $56 Fr..
MT
10/15VC DAILY : Question: What Makes Decentralized Finance Attractive to Investors?
DJ
10/15THESE BOOTS ARE MADE FOR JABBING : Sales buoyed by Covid test demand
AQ
10/14Health Care Up After UnitedHealth Boosts Earnings View -- Health Care Roundup
DJ
10/14S&P 500 surges, biggest daily percentage rise since March on earnings, data
RE
10/14US Stocks Rally as Strong Bank Earnings, Pandemic-Low Jobless Claims Lift Market Sentim..
MT
10/14CLOSE UPDATE : US Stocks Rally as Strong Bank Earnings, Pandemic-Low Jobless Claims Lift M..
MT
10/14WALGREENS BOOTS ALLIANCE : Management's discussion and analysis of financial condition and..
AQ
More news
Analyst Recommendations on WALGREENS BOOTS ALLIANCE, INC.
More recommendations
Financials (USD)
Sales 2022 134 B - -
Net income 2022 3 335 M - -
Net Debt 2022 9 466 M - -
P/E ratio 2022 12,2x
Yield 2022 4,04%
Capitalization 41 558 M 41 558 M -
EV / Sales 2022 0,38x
EV / Sales 2023 0,36x
Nbr of Employees 258 500
Free-Float 61,0%
Chart WALGREENS BOOTS ALLIANCE, INC.
Duration : Period :
Walgreens Boots Alliance, Inc. Technical Analysis Chart | WBA | US9314271084 | MarketScreener
Technical analysis trends WALGREENS BOOTS ALLIANCE, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 22
Last Close Price 48,01 $
Average target price 53,50 $
Spread / Average Target 11,4%
EPS Revisions
Managers and Directors
Rosalind Gates Brewer Chief Executive Officer & Director
James Kehoe Global Chief Financial Officer & Executive VP
Stefano Pessina Executive Chairman
Francesco Tinto Global Chief Information Officer & Senior VP
Ornella Barra Chief Operating Officer
Sector and Competitors